Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment

We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance no...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlin, Aaron F., Clark, Alex E., Chaillon, Antoine, Garretson, Aaron F., Bray, William, Porrachi, Magali, Santos, AsherLev T., Smith, Davey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128786/
https://www.ncbi.nlm.nih.gov/pubmed/35611335
http://dx.doi.org/10.21203/rs.3.rs-1662783/v1
_version_ 1784712618462674944
author Carlin, Aaron F.
Clark, Alex E.
Chaillon, Antoine
Garretson, Aaron F.
Bray, William
Porrachi, Magali
Santos, AsherLev T.
Smith, Davey M.
author_facet Carlin, Aaron F.
Clark, Alex E.
Chaillon, Antoine
Garretson, Aaron F.
Bray, William
Porrachi, Magali
Santos, AsherLev T.
Smith, Davey M.
author_sort Carlin, Aaron F.
collection PubMed
description We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.
format Online
Article
Text
id pubmed-9128786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-91287862022-05-25 Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment Carlin, Aaron F. Clark, Alex E. Chaillon, Antoine Garretson, Aaron F. Bray, William Porrachi, Magali Santos, AsherLev T. Smith, Davey M. Res Sq Article We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence. American Journal Experts 2022-05-18 /pmc/articles/PMC9128786/ /pubmed/35611335 http://dx.doi.org/10.21203/rs.3.rs-1662783/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Carlin, Aaron F.
Clark, Alex E.
Chaillon, Antoine
Garretson, Aaron F.
Bray, William
Porrachi, Magali
Santos, AsherLev T.
Smith, Davey M.
Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title_full Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title_fullStr Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title_full_unstemmed Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title_short Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
title_sort virologic and immunologic characterization of covid-19 recrudescence after nirmatrelvir/ritonavir treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128786/
https://www.ncbi.nlm.nih.gov/pubmed/35611335
http://dx.doi.org/10.21203/rs.3.rs-1662783/v1
work_keys_str_mv AT carlinaaronf virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT clarkalexe virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT chaillonantoine virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT garretsonaaronf virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT braywilliam virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT porrachimagali virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT santosasherlevt virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment
AT smithdaveym virologicandimmunologiccharacterizationofcovid19recrudescenceafternirmatrelvirritonavirtreatment

Ejemplares similares